Glucagon receptor antagonists-4 are primarily used in the research and development of treatments for metabolic disorders, particularly type 2 diabetes. By blocking the glucagon receptor, these compounds help reduce the production of glucose in the liver, which can lower blood sugar levels in patients. This mechanism is especially beneficial for individuals who struggle with hyperglycemia despite insulin therapy. Additionally, these antagonists are being studied for their potential role in managing obesity, as they may influence energy metabolism and appetite regulation. Their application in preclinical and clinical studies aims to provide new therapeutic options for improving glycemic control and overall metabolic health.